Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: An NCI-CPTC initiative perspective

Proteomics - Clinical Applications

Volumn 4, Issue 12, 2010, Pages 904-914

  Rodriguez, Henry ^a   Rivers, Robert ^a   Kinsinger, Christopher ^a   Mesri, Mehdi ^a   Hiltke, Tara ^a   Rahbar, Amir ^a   Boja, Emily ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biomarker qualification (clinical validation); Biomarker verification (analytical validation); Biomarkers; MRM MS; Quantification

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TROPONIN; TUMOR MARKER;

ACCURACY; AUTOMATION; CANCER RESEARCH; CATION EXCHANGE; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH THROUGHPUT SCREENING; ISOTOPE DILUTION ASSAY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MULTIPLE REACTION MONITORING; MULTIPLE REACTION MONITORING MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEOMICS; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZATION;

CLINICAL LABORATORY TECHNIQUES; DIAGNOSTIC TEST APPROVAL; MASS SPECTROMETRY; NATIONAL CANCER INSTITUTE (U.S.); PROTEOMICS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 78649694616     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201000057     Document Type: Review

References (55)

1. Atkinson, A. J., Colburn, W. A., Degruttola, V. G., Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69, 89-95.
2. Zhang, X., Li, L., Wei, D., Yap, Y., Chen, F., Moving cancer diagnostics from bench to bedside. Trends Biotechnol. 2007, 25, 166-173.
3. Anderson, L., Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J. Physiol. 2005, 563, 23-60.
4. Etzioni, R., Urban, N., Ramsey, S., McIntosh, M. et al., The case for early detection. Nat. Rev. Cancer 2005, 3, 243-252.
5. Rifai, N., Gillette, M. A., Carr, S. A., Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 24, 971-983.
6. García-Foncillas, J., Bandrés, E., Zárate, R., Remírez, N., Proteomic analysis in cancer research: potential application in clinical use. Clin. Transl. Oncol. 2006, 8, 250-261.
7. Kelleher, M. T., Fruhwirth, G., Patel, G., Ofo, E. et al., The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients. Target Oncol. 2009, 4, 235-252.
8. Wang, P., Whiteaker, J. R., Paulovich, A. G., The evolving role of mass spectrometry in cancer biomarker discovery. Cancer Biol. Ther. 2009, 8, 1083-1094.
9. Goodsaid, F. M., Frueh, F. W., Mattes, W., Strategic paths for biomarker qualification. Toxicology 2008, 245, 219-223.
10. Findeisen, P., Neumaier, M., Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective. Clin. Chem. Lab. Med. 2009, 47, 666-684.
11. Addona, T. A., Abbatiello, S. E., Schilling, B., Skates, S. J. et al., Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat. Biotechnol. 2009, 27, 633-641.
12. Moritz, R. L., Clippingdale, A. B., Kapp, E. A., Eddes, J. S., Application of 2-D free-flow electrophoresis/RP-HPLC for proteomic analysis of human plasma depleted of multi high-abundance proteins. Proteomics 2005, 5, 3402-3413.
13. Li, Y., Lee, H. J., Corn, R. M., Detection of protein biomarkers using RNA aptamer microarrays and enzymatically amplified surface plasmon resonance imaging. Anal. Chem. 2007, 79, 1082-1088.
14. Pierobon, M., Calvert, V., Belluco, C., Garaci, E. et al., Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker. Clin. Colorectal Cancer 2009, 8, 110-117.
15. Ramachandran, N., Raphael, J. V., Hainsworth, E., Demirkan, G. et al., Next-generation high-density self-assembling functional protein arrays. Nat. Methods 2008, 5, 535-538.
16. Kuhn, E., Addona, T., Keshishian, H., Burgess, M. et al., Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin. Chem. 2009, 55, 1108-1117.
17. Beirne, P., Pantelidis, P., Charles, P., Wells, A. U. et al., Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis. Eur. Respir. J. 2009, 34, 1376-1382.
18. Polanski, M., Anderson, L., A list of candidate cancer biomarkers for targeted proteomics. Biomark. Insights 2007, 1, 1-48.
19. Anderson, N. L., The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin. Chem. 2010, 56, 177-185.
20. Anderson, L., Hunter, C. L., Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell Proteomics 2006, 5, 573-588.
21. Paulovich, A. G., Whiteaker, J. R., Hoofnagle, A. N., Wang, P., The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin. Appl. 2008, 2, 1386-1402.
22. Makawita, S., Diamandis, E. P., The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin. Chem. 2010, 56, 212-222.
23. Turck, C. W., Falick, A. M., Kowalak, J. A., Lane, W. S., The Association of Biomolecular Resource Facilities Proteomics Research Group 2006 study: relative protein quantitation. Mol. Cell Proteomics 2007, 6, 1291-1298.
24. Arnott, D., Gawinowicz, M. A., Kowalak, J. A., Lane, W. S., ABRF-PRG04: differentiation of protein isoforms. J. Biomol. Tech. 2007, 18, 124-134.
25. Falick, A. M., Kowalak, J. A., Lane, W. S., Phinney, B. S., ABRF-PRG05: de novo peptide sequence determination. J. Biomol. Tech. 2008, 19, 251-257.
26. Bell, A. W., Deutsch, E. W., Au, C. E., Kearney, R. E. et al., A HUPO test sample study reveals common problems in mass spectrometry-based proteomics. Nat. Methods 2009, 6, 423-430.
27. Paulovich, A. G., Billheimer, D., Ham, A. J., Vega-Montoto, L. et al., Interlaboratory study characterizing a yeast performance standard for benchmarking LC-MS platform performance. Mol. Cell Proteomics 2010, 9, 242-254.
28. Rodriguez, H., Tezak, Z., Mesri, M., Carr, S. A. et al., Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics. Clin. Chem. 2010, 56, 237-243.
29. Regnier, F. E., Skates, S. J., Mesri, M., Rodriguez, H. et al., Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration. Clin. Chem. 2010, 56, 165-171.
30. MacLean, B., Tomazela, D. M., Shulman, N., Chambers, M. et al., Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics. 2010, 26, 966-968.
31. Gerszten, R. E., Carr, S. A., Sabatine, M., Integration of proteomic-based tools for improved biomarkers of myocardial injury. Clin. Chem. 2010, 56, 194-201.
32. Keshishian, H., Addona, T., Burgess, M., Kuhn, E., Carr, S. A., Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell Proteomics 2007, 6, 2212-2229.
33. Anderson, N. L., Jackson, A., Smith, D., Hardie, D. et al., SISCAPA peptide enrichment on magnetic beads using an in-line bead trap device. Mol. Cell Proteomics 2009, 8, 995-1005.
34. Ciccimaro, E., Hanks, S. K., Yu, K. H., Blair, I. A., Absolute quantification of phosphorylation on the kinase activation loop of cellular focal adhesion kinase by stable isotope dilution liquid chromatography/mass spectrometry. Anal Chem. 2009, 81, 3304-3313.
35. Hoofnagle, A. N., Becker, J. O., Wener, M. H., Heinecke, J. W., Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin. Chem. 2008, 54, 1796-1804.
36. Drake, P. M., Cho, W., Li, B., Prakobphol, A. et al., Sweetening the pot: adding glycosylation to the biomarker discovery equation. Clin. Chem. 2010, 56, 223-236.
37. Reid, J. D., Holmes, D. T., Mason, D. R., Shah, B., Borchers, C. H., Towards the development of an immunoMALDI (iMALDI) mass spectrometry assay for the diagnosis of hypertension. J. Am. Soc. Mass Spectrom. 2010, 21, 1680-1686.
38. Jiang, J., Parker, C. E., Fuller, J. R., Kawula, T. H., Borchers, C. H., An immunoaffinity tandem mass spectrometry (iMALDI) assay for detection of Francisella tularensis. Anal. Chim. Acta 2007, 605, 70-79.
39. Hoofnagle, A. N., Wener, M. H., The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J. Immunol. Methods. 2009, 347, 3-11.
40. Zhao, L., Lee, B. Y., Brown, D. A., Molloy, M. P., Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res. 2009, 69, 7696-7703.
41. 18O-labeling to identify biomarkers for cholangiocarcinoma. J Proteome Res. 2008, 7, 4670-4677.
42. Pan, C., Olsen, J. V., Daub, H., Mann, M., Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol. Cell Proteomics 2009, 8, 2796-2808.
43. Zamò, A., Cecconi, D., Proteomic analysis of lymphoid and haematopoietic neoplasms: there's more than biomarker discovery. J. Proteomics 2010, 73, 508-520.
44. Piersma, S. R., Fiedler, U., Span, S., Lingnau, A. et al., Workflow comparison for label-free, quantitative secretome proteomics for cancer biomarker discovery: method evaluation, differential analysis, and verification in serum. J. Proteome Res. 2010, 9, 1913-1922.
45. Zheng, G., Patolsky, F., Cui, Y., Wang, W. U., Lieber, C. M., Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nat. Biotechnol. 2005, 23, 1294-1301.
46. Archakov, A. I., Ivanov, Y, D., Analytical nanobiotechnology for medicine diagnostics. Mol. Biosyst. 2007, 3, 336-342.
47. Sakamoto, J. H., van de Ven, A. L., Godin, B., Blanco, E. et al., Enabling individualized therapy through nanotechnology. Pharmacol. Res. 2010, 62, 57-89.
48. Hamburg, M. A., Collins, F. S., The path to personalized medicine. N. Engl. J. Med. 2010, 363, 301-304.
49. Workman, P., Strategies for treating cancers caused by multiple genome abnormalities: from concepts to cures? Curr. Opin. Investig. Drugs 2003, 4, 1410-1415.
50. Nibbe, R. K., Chance, M. R., Approaches to biomarkers in human colorectal cancer: looking back, to go forward. Biomark. Med. 2009, 3, 385-396.
51. Jolly Graham, A., Potti, A., Translating genomics into clinical practice: applications in lung cancer. Curr. Oncol. Rep. 2009, 11, 263-268.
52. Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V. et al., Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010, 17, 98-110.
53. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455, 1061-1068.
54. Hodgson, J. G., Yeh, R. F., Ray, A., Wang, N. J. et al., Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. NeuroOncology 2009, 11, 477-487.
55. International Cancer Genome Consortium. International network of cancer genome projects. Nature. 2010, 464, 993-998.